FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316668818> ?p ?o ?g. }

• W2316668818 endingPage "109.e4" @default.
• W2316668818 startingPage "97" @default.
• W2316668818 abstract "Physicians frequently encounter patients with immune-mediated diseases and a history of malignancy. There are limited data on the safety of immunosuppressive therapy for these patients. Published studies have been small with few events, precluding robust estimates of risk.We searched Medline, EMBASE, and conference proceedings for terms related to immune-mediated disease, immune-suppressive therapy, and cancer recurrence from inception to April 2015. We included 16 studies (9 of patients with rheumatoid arthritis, 8 of patients with inflammatory bowel disease, and 1 of patients with psoriasis) and stratified studies by type of immune-suppressive therapy (monoclonal antibodies to tumor necrosis factor [anti-TNF], conventional immune-modulatory agents, or no immune suppression). A random-effects meta-analysis was performed to calculate the pooled incidence rates as well as risk differences between the various treatments.Our analysis included 11,702 persons contributing 31,258 person-years (p-y) of follow-up evaluation after a prior diagnosis of cancer. Rates of cancer recurrence were similar among individuals receiving anti-TNF therapy (33.8 per 1000 p-y), immune-modulator therapy (36.2 per 1000 p-y), or no immunosuppression (37.5 per 1000 p-y), but were numerically higher among patients receiving combination immune suppression (54.5 per 1000 p-y) (P > .1 for all). Subgroup analysis of new and recurrent cancers separately, type of immune-modulator therapy, or immune-mediated disease showed similar results, with no increase in risk. We found similar pooled incidence values for new or primary cancers when immunosuppression was initiated within 6 years (33.6 per 1000 p-y for immune-modulatory agents and 43.7 per 1000 p-y for anti-TNF agents) vs more than 6 years after the index cancer (32.9 per 1000 p-y for immune-modulatory agents, P = .86; and 21.0 per 1000 p-y for anti-TNF agents, P = .43).In a meta-analysis of 16 studies, we observed similar rates of cancer recurrence among individuals with prior cancer who received no immunosuppression, anti-TNF therapy, immune-modulator therapy, or combination treatments. Prospective studies are needed to ascertain optimal intervals for re-initiation of immune-suppressive therapies for individuals with specific cancers." @default.
• W2316668818 created "2016-06-24" @default.
• W2316668818 creator A5009680823 @default.
• W2316668818 creator A5010004602 @default.
• W2316668818 creator A5015470174 @default.
• W2316668818 creator A5041936168 @default.
• W2316668818 creator A5055266545 @default.
• W2316668818 creator A5056339603 @default.
• W2316668818 creator A5073977144 @default.
• W2316668818 date "2016-07-01" @default.
• W2316668818 modified "2023-10-16" @default.
• W2316668818 title "Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis" @default.
• W2316668818 cites W1410441244 @default.
• W2316668818 cites W141770798 @default.
• W2316668818 cites W1761300068 @default.
• W2316668818 cites W187504565 @default.
• W2316668818 cites W1892676932 @default.
• W2316668818 cites W1969613681 @default.
• W2316668818 cites W1970754981 @default.
• W2316668818 cites W1981272396 @default.
• W2316668818 cites W1981437024 @default.
• W2316668818 cites W1989393620 @default.
• W2316668818 cites W1992918232 @default.
• W2316668818 cites W1996398553 @default.
• W2316668818 cites W1996491123 @default.
• W2316668818 cites W2002647452 @default.
• W2316668818 cites W2004499699 @default.
• W2316668818 cites W2004608617 @default.
• W2316668818 cites W2005490856 @default.
• W2316668818 cites W2007163992 @default.
• W2316668818 cites W2007842607 @default.
• W2316668818 cites W2008687669 @default.
• W2316668818 cites W2019150265 @default.
• W2316668818 cites W2023380965 @default.
• W2316668818 cites W2023627077 @default.
• W2316668818 cites W2024763754 @default.
• W2316668818 cites W2035481305 @default.
• W2316668818 cites W2048717004 @default.
• W2316668818 cites W2051224400 @default.
• W2316668818 cites W2055176162 @default.
• W2316668818 cites W2057890650 @default.
• W2316668818 cites W2062694326 @default.
• W2316668818 cites W2080037503 @default.
• W2316668818 cites W2080450248 @default.
• W2316668818 cites W2094638634 @default.
• W2316668818 cites W2100942700 @default.
• W2316668818 cites W2103120331 @default.
• W2316668818 cites W2105058392 @default.
• W2316668818 cites W2105311242 @default.
• W2316668818 cites W2105532585 @default.
• W2316668818 cites W2107328434 @default.
• W2316668818 cites W2109445459 @default.
• W2316668818 cites W2112604373 @default.
• W2316668818 cites W2113633952 @default.
• W2316668818 cites W2119665774 @default.
• W2316668818 cites W2119723369 @default.
• W2316668818 cites W2120393706 @default.
• W2316668818 cites W2126807394 @default.
• W2316668818 cites W2127143707 @default.
• W2316668818 cites W2133915381 @default.
• W2316668818 cites W2133957166 @default.
• W2316668818 cites W2142796823 @default.
• W2316668818 cites W2144399580 @default.
• W2316668818 cites W2161227681 @default.
• W2316668818 cites W2170800858 @default.
• W2316668818 cites W2171202562 @default.
• W2316668818 cites W2289512668 @default.
• W2316668818 cites W2330695133 @default.
• W2316668818 cites W2418358993 @default.
• W2316668818 cites W2560367415 @default.
• W2316668818 cites W2978253250 @default.
• W2316668818 cites W2978827945 @default.
• W2316668818 cites W4210768724 @default.
• W2316668818 cites W4235790631 @default.
• W2316668818 cites W4237793802 @default.
• W2316668818 cites W72186756 @default.
• W2316668818 doi "https://doi.org/10.1053/j.gastro.2016.03.037" @default.
• W2316668818 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4925196" @default.
• W2316668818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27039969" @default.
• W2316668818 hasPublicationYear "2016" @default.
• W2316668818 type Work @default.
• W2316668818 sameAs 2316668818 @default.
• W2316668818 citedByCount "116" @default.
• W2316668818 countsByYear W23166688182016 @default.
• W2316668818 countsByYear W23166688182017 @default.
• W2316668818 countsByYear W23166688182018 @default.
• W2316668818 countsByYear W23166688182019 @default.
• W2316668818 countsByYear W23166688182020 @default.
• W2316668818 countsByYear W23166688182021 @default.
• W2316668818 countsByYear W23166688182022 @default.
• W2316668818 countsByYear W23166688182023 @default.
• W2316668818 crossrefType "journal-article" @default.
• W2316668818 hasAuthorship W2316668818A5009680823 @default.
• W2316668818 hasAuthorship W2316668818A5010004602 @default.
• W2316668818 hasAuthorship W2316668818A5015470174 @default.
• W2316668818 hasAuthorship W2316668818A5041936168 @default.
• W2316668818 hasAuthorship W2316668818A5055266545 @default.
• W2316668818 hasAuthorship W2316668818A5056339603 @default.

• next